United Therapeutics Corporation · NASDAQ:UTHR
Rothblatt Martine A sold 7,580 United Therapeutics Corporation shares (Form 4)
Traded Sep 30, 2026 · Filed Oct 1, 2026
On Sep 30, 2026, Rothblatt Martine A (Director, Chairperson & CEO) sold 7,580 United Therapeutics Corporation shares at an average US$517.97 for US$3.93M under a trading plan, leaving 326,363 shares. Filed Oct 1, 2026 (Form 4).
- Sold
- 7,580 shares
- Price
- US$517.97 average (US$476.14 to US$546.23)
- Value
- US$3.93M
- Holding after
- 326,363 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, Chairperson & CEO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Common Stock | Option exercise | 9,500 | US$117.76 | 333,943 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 161 | US$476.14 | 333,782 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 749 | US$477.43 | 333,033 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 650 | US$478.47 | 332,383 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 359 | US$479.67 | 332,024 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 601 | US$480.79 | 331,423 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 160 | US$482.36 | 331,263 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 80 | US$487.79 | 331,183 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 40 | US$495.32 | 331,143 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 40 | US$511.37 | 331,103 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 80 | US$514.90 | 331,023 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 80 | US$517.17 | 330,943 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 80 | US$523.36 | 330,863 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 80 | US$524.62 | 330,783 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 80 | US$526.09 | 330,703 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 160 | US$531.11 | 330,543 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 160 | US$536.52 | 330,383 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 200 | US$537.67 | 330,183 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 40 | US$538.65 | 330,143 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 480 | US$540.78 | 329,663 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 580 | US$541.76 | 329,083 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 600 | US$543.25 | 328,483 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 840 | US$544.05 | 327,643 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 920 | US$545.13 | 326,723 | Indirect |
| Sep 30, 2026 | Common Stock | Sale | 360 | US$546.23 | 326,363 | Indirect |
Source
Related
- United Therapeutics Corporation
- Rothblatt Martine A
- United Therapeutics Corporation shareholders
- Form 4 · Rothblatt Martine A · Oct 22, 2026
- Form 4 · Rothblatt Martine A · Oct 21, 2026
- Form 4 · Rothblatt Martine A · Oct 20, 2026
- Form 4 · Rothblatt Martine A · Oct 19, 2026
- Form 4 · Rothblatt Martine A · Oct 16, 2026
- Schedule 13G/A · Rothblatt Martine A · Aug 14, 2026
- Schedule 13G/A · Wellington Management Group LLP · Aug 13, 2026
- Schedule 13G · Vanguard Capital Management LLC · Apr 30, 2026
- Schedule 13G/A · The Vanguard Group · Mar 27, 2026
- Schedule 13G · Wellington Management Group LLP · Feb 10, 2026